| Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis CBA Paterniti MO, Bi Y, Rekić D, Wang Y, Karimi-Shah BA Annals of the American Thoracic Society, 2017 | 159 | 2017 |
| An oral antisense oligonucleotide for PCSK9 inhibition P Gennemark, K Walter, N Clemmensen, D Rekić, CAM Nilsson, ... Science Translational Medicine 13 (593), eabe9117, 2021 | 97 | 2021 |
| Clinical drug–drug interaction evaluations to inform drug use and enable drug access D Rekić, KS Reynolds, P Zhao, L Zhang, K Yoshida, M Sachar, MP Miller, ... Journal of pharmaceutical sciences 106 (9), 2214-2218, 2017 | 76 | 2017 |
| In vitro–in vivo extrapolation of metabolism-and transporter-mediated drug–drug interactions—overview of basic prediction methods K Yoshida, P Zhao, L Zhang, DR Abernethy, D Rekić, KS Reynolds, ... Journal of pharmaceutical sciences 106 (9), 2209-2213, 2017 | 70 | 2017 |
| Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine L Barregard, D Rekić, M Horvat, L Elmberg, T Lundh, O Zachrisson Toxicological Sciences 120 (2), 499-506, 2011 | 64 | 2011 |
| In silico prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype D Rekić, D Röshammar, J Mukonzo, M Ashton British journal of clinical pharmacology 71 (4), 536-543, 2011 | 54 | 2011 |
| HIVAIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects JK Mukonzo, S Nanzigu, D Rekić, P Waako, D Roshammar, M Ashton, ... Clinical pharmacokinetics 50 (8), 531-540, 2011 | 38 | 2011 |
| Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy D Rekić, O Clewe, D Röshammar, L Flamholc, A Sönnerborg, ... The AAPS journal 13 (4), 598-605, 2011 | 20 | 2011 |
| AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval D Rekić, I Azarov, J Knöchel, V Sokolov, C Nilsson, L Wernevik, D Han, ... British Journal of Clinical Pharmacology 88 (11), 4839-4844, 2022 | 12 | 2022 |
| QT prolongation risk assessment in oncology: lessons learned from small‐molecule new drug applications approved during 2011‐2019 S Cohen‐Rabbie, AC Berges, D Rekić, J Parkinson, C Dota, ... The Journal of Clinical Pharmacology 61 (8), 1106-1117, 2021 | 12 | 2021 |
| Model based design and analysis of phase II HIV-1 trials D Rekić, D Röshammar, USH Simonsson Journal of pharmacokinetics and pharmacodynamics 40, 487-496, 2013 | 12 | 2013 |
| Etesian: a phase 2B study of the efficacy, safety and tolerability of Azd8233, a Pcsk9-targeted antisense oligonucleotide, in patients with dyslipidemia MJ Koren, A Hofherr, J Schumi, D Rekic, J Knochel, CAM Nilsson, ... Journal of the American College of Cardiology 79 (9_Supplement), 1475-1475, 2022 | 11 | 2022 |
| Pharmacokinetics of roxadustat: a population analysis of 2855 dialysis-and non-dialysis-dependent patients with chronic kidney disease D Rekić, V Kerbusch-Herben, M Någård, J Chou, J Huang, C Bradley, ... Clinical Pharmacokinetics 60, 759-773, 2021 | 10 | 2021 |
| Dapagliflozin pharmacokinetics is similar in adults with type 1 and type 2 diabetes mellitus J Melin, W Tang, D Rekić, B Hamrén, RC Penland, DW Boulton, ... The Journal of Clinical Pharmacology 62 (10), 1227-1235, 2022 | 9 | 2022 |
| A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated … J Leander, M Sunnåker, D Rekić, S Aksenov, UG Eriksson, S Johansson, ... Journal of Pharmacokinetics and Pharmacodynamics 48, 525-541, 2021 | 9 | 2021 |
| A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients Y Bi, D Rekić, MO Paterniti, J Chen, A Marathe, BA Chowdhury, ... Journal of pharmacokinetics and pharmacodynamics 48, 55-67, 2021 | 7 | 2021 |
| A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II J Knöchel, C Nilsson, B Carlsson, L Wernevik, A Hofherr, P Gennemark, ... CPT: pharmacometrics & systems pharmacology 11 (12), 1569-1577, 2022 | 6 | 2022 |
| Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data Y Aoki, CS Cabrera, M Ouwens, K Bamberg, J Nyström, I Raz, BM Scirica, ... Plos one 17 (6), e0269970, 2022 | 6 | 2022 |
| Concentration‐QT modelling in early clinical oncology settings: Simulation evaluation of performance G Cantet, A Berges, R O'Sullivan, S Cohen‐Rabbie, C Dota, V Dubois, ... British Journal of Clinical Pharmacology 88 (3), 1010-1019, 2022 | 5 | 2022 |
| Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations V Voronova, M Cullberg, P Delff, J Parkinson, C Dota, G Schiavon, ... British Journal of Clinical Pharmacology 88 (2), 858-864, 2022 | 4 | 2022 |
Jane KnöchelUniversity of Potsdam, AstraZeneca在 uni-potsdam.de 的电子邮件经过验证
